Barclays PLC Raises Stake in MediWound Ltd. (NASDAQ:MDWD)

Barclays PLC boosted its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 311.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 11,163 shares of the biopharmaceutical company’s stock after purchasing an additional 8,449 shares during the period. Barclays PLC owned approximately 0.10% of MediWound worth $202,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. MetLife Investment Management LLC purchased a new position in MediWound during the 3rd quarter worth $89,000. Rhumbline Advisers purchased a new position in MediWound during the 2nd quarter worth $131,000. Point72 Asset Management L.P. purchased a new position in MediWound during the 3rd quarter worth $212,000. Bank of New York Mellon Corp purchased a new position in MediWound during the 2nd quarter worth $342,000. Finally, State Street Corp grew its position in MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 45,529 shares during the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on shares of MediWound from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 27th.

MediWound Stock Performance

MDWD stock opened at $17.75 on Tuesday. MediWound Ltd. has a one year low of $11.04 and a one year high of $24.00. The stock has a market capitalization of $191.45 million, a PE ratio of -6.12 and a beta of 0.80. The company has a fifty day moving average of $17.37 and a 200-day moving average of $17.57.

MediWound (NASDAQ:MDWD) last released its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same quarter last year, the firm posted ($0.24) earnings per share. Equities analysts forecast that MediWound Ltd. will post -2.6 earnings per share for the current fiscal year.

MediWound Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.